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Abstract
Background: Glaucoma is the leading cause of irreversible blindness. Although primary open-angle glaucoma is
more common, primary angle-closure glaucoma (PACG) is more likely to result in irreversible blindness. By 2020, 5·3
million people worldwide will be blind because of PACG. The current standard care for PACG is a stepped approach
of a combination of laser iridotomy surgery (to open the drainage angle) and medical treatment (to reduce
intraocular pressure). If these treatments fail, glaucoma surgery (eg, trabeculectomy) is indicated. It has been
proposed that, because the lens of the eye plays a major role in the mechanisms leading to PACG, early clear lens
extraction will improve glaucoma control by opening the drainage angle. This procedure might reduce the need for
drugs and glaucoma surgery, maintain good visual acuity, and improve quality of life compared with standard care.
EAGLE aims to evaluate whether early lens extraction improves patient-reported, clinical outcomes, and cost-
effectiveness, compared with standard care.
Methods/Design: EAGLE is a multicentre pragmatic randomized trial. All people presenting to the recruitment centres
in the UK and east Asia with newly diagnosed PACG and who are at least 50 years old are eligible.
The primary outcomes are EQ-5D, intraocular pressure, and incremental cost per quality adjusted life year (QALY) gained.
Other outcomes are: vision and glaucoma-specific patient-reported outcomes, visual acuity, visual field, angle closure,
number of medications, additional surgery (e.g., trabeculectomy), costs to the health services and patients, and adverse
events.
A single main analysis will be done at the end of the trial, after three years of follow-up. The analysis will be based
on all participants as randomized (intention to treat). 400 participants (200 in each group) will be recruited, to have
90% power at 5% significance level to detect a difference in EQ-5D score between the two groups of 0·05, and a
mean difference in intraocular pressure of 1·75 mm Hg. The study will have 80% power to detect a difference of
15% in the glaucoma surgery rate. Trial Registration: ISRCTN44464607.
Background
The World Health Organization ranks glaucoma as the
second most common cause of blindness after cataract,
and as the leading cause of irreversible blindness. There
are two types of glaucoma: open angle and angle closure.
Although primary open angle glaucoma is the more com-
mon, primary angle closure glaucoma (PACG) is the
more severe (more likely to result in irreversible blind-
ness if not properly treated) [1]. By 2020 PACG will affect
20 million people, and 5.3 million will be blind [2]. In the
UK, PACG affects between 50,000 and 100,000 people,
but is estimated to cause 1000 people to suffer irreversi-
ble blindness every year, and many more live with the
disability and reduced quality of life associated with
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rest of the world. Older age and female gender are demo-
graphic risk factors. Having a small eye and thus hyper-
metropia (far-sightedness) is also an important risk
factor. Blindness is costly to health care, society and indi-
viduals [3,4]. The effect of severe glaucoma on patients
quality of life is profound (the utility associated with
severe visual impairment is approximately half that of full
health) [5]. The number of people diagnosed with PACG
is predicted to increase substantially over the next few
years as the result of an ageing population, increased
optometric screening, and raised awareness of narrow
angle pathologies among clinicians [6].
Within the eye the anterior chamber angle is located
between the peripheral iris and the cornea. Within the
anterior chamber angle the trabecular meshwork is
responsible for aqueous humour (intraocular fluid) out-
flow. Primary angle closure (PAC) is characterised by
contact between the peripheral iris and the trabecular
meshwork (appositional closure) leading to an elevated
IOP. This contact can ultimately result in a permanent
(synechial) closure of the angle [7]. PACG occurs when
high IOP damages the optic nerve and leads to visual
loss and, if untreated or inadequately treated, blindness
results. PACG occurs due to anatomic factors (such as a
small eye, large lens, thick peripheral iris, anterior posi-
tion of ciliary processes) within the eye. People with
PAC and PACG can be symptomatic as an acute angle
closure crisis, or more commonly asymptomatic.
The current standard care for PACG is a stepped
approach of a combination of surgery (laser or inci-
sional) and medical management. Initial surgery uses a
laser to make a small hole in the iris (laser iridotomy
[LI]) to open the drainage angle, and often eye drops
are required as an adjunct to LI to further reduce the
IOP. There are several types of drops used to lower IOP
but prostaglandin and beta-blocker treatments are the
most commonly used. If the drainage pathway is still
closed after LI, alternative laser treatment whereby iris
tissue is pulled away from the drainage angle, laser per-
ipheral iridoplasty (LPI) is an option. If these first line
treatments fail glaucoma surgery (e.g., trabeculectomy)
is then indicated. Glaucoma surgery may fail to control
the IOP, and in PACG complications are more likely
(such as flat anterior chamber and malignant glaucoma)
than for other types of glaucoma [8].
These standard approaches to PACG management
have been noted to have variable success. A new
approach to the management of patients with PACG
(lens extraction by phacoemulsification) has, however,
gained recent interest among specialists internationally.
The lens of the eye plays a major role in the mechan-
isms leading to PACG including pupillary block and
angle crowding. The hypothesis is that PACG could be
treated by removing the lens (by phacoemulsification).
For glaucoma patients with cataract, lens extraction is
always required. However, in the absence of cataract,
whether to extract the lens, and the timing of such
intervention, remains open to debate. It is likely that
many people with PACG (up to 50%) will go on to
develop cataracts and require surgery due to ageing and
to the effect of conventional glaucoma treatment [9],
which may accelerate cataract progression but by this
s t a g ei r r e v e r s i b l eg l a u c o m ad a m a g ea n ds i g h tl o s sm a y
have occurred. It is proposed that early lens extraction
will improve glaucoma control by opening the drainage
angle. This should reduce the need for medications
and trabeculectomy, maintain good visual acuity, and
improve quality of life compared with standard care.
It will also improve the visual function in patients
with hypermetropia (found in the majority of PACG
patients), by correcting this refractive error.
A 2006 Cochrane systematic review by Friedman and
colleagues [10] of lens extraction for PACG found no
RCTs of lens extraction versus alternative treatment
options for PACG. Two included non-randomized stu-
dies were deemed of poor quality. The authors con-
cluded that there was not enough evidence to assess the
superiority of lens extraction over other interventions to
control IOP in this condition, and RCTs comparing lens
extraction with alternative treatment options were
required.
Methods/Design
The following question will be addressed, primarily in
terms of Quality of Life and vision as well as the intraocu-
lar pressure, stability of the disease and the safety of the
interventions at three years after randomisation: For peo-
ple with PACG what is the clinical and cost-effectiveness
of early lens extraction surgery compared with standard
care (usually laser iridotomy followed by a sequence of
medical therapy and glaucoma surgery (e.g., trabeculect-
omy or another glaucoma operation)?
The hypotheses being tested are that those rando-
mized to early lens extraction will have a higher EQ-5D
q u a l i t yo fl i f eq u e s t i o n n a i r es c o r e( m e a nd i f f e r e n c eo f
0.05); lower IOP (mean difference of 1.75 mmHg); and a
15% lower glaucoma surgery rate than those randomized
to standard care at three years.
Participants and eligibility
All people presenting, in the recruitment centres in the
UK and East Asia, with newly diagnosed PACG. The
inclusion criteria are:
￿ Diagnosis: either one of the following two types of
patients: (1) primary angle closure glaucoma (PACG) or
(2) primary angle closure (PAC) with IOP ≥ 30 mm Hg
at diagnosis. Glaucoma is defined as: reproducible
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defect, in at least 2 consecutive visual fields, of two or
more contiguous points with P < 0.01 loss or greater, or
three or more contiguous points with P <0 . 0 5l o s so r
greater in the pattern deviation plot, or abnormal Glau-
coma Hemifield Test), or Glaucomatous optic neuropa-
thy with localised absence of the neural rim or, cup disc
ratio of 0.7 or more, or asymmetry of cup disc ratio of
0.2 or more in similar sized eyes/optic discs, and an IOP
> 21 mm Hg on one or more occasions,
￿ Newly diagnosed, i.e., either (i) untreated or (ii)
under medical treatment for six months or less;
￿ Angle closure (iridotrabecular contact), either apposi-
tional or synechial in 180 degrees or more. Primary angle
closure with raised intraocular pressure (IOP ≥ 30 mm
Hg on at least one occasion). Visual field loss and glauco-
matous optic neuropathy, as defined above, are not
present,
￿ Patient must be phakic in the affected eye(s);
￿ The participant shall be 50 years or older,
￿ Written informed consent obtained.
The exclusion criteria are:
￿ Advanced glaucoma in the potentially eligible eye as
determined by either: (i) visual field loss (mean deviation
worse than -15 dB) or (ii) cup-disc-ratio ≥ 0.9;
￿ Previously diagnosed acute angle closure attack in
the potentially eligible eye;
￿ Increased surgical risk: e.g., corneal opacity, Fuch’s
endothelial dystrophy; pseudoexfoliation, previous
vitreo-retinal surgery, not able to be positioned to
undergo standard technique;
￿ Symptomatic cataract in either eye. Symptomatic
cataract is defined as sufficient lens opacity such that
one would normally recommend cataract surgery to
relieve visual symptoms (i.e. if the participant did not
have glaucoma one would recommend lens extraction).
￿ Any intraocular procedure or laser treatment,
including previous cataract surgery, trabeculoplasty,
gonioplasty, or laser iridotomy in the index eye;
￿ Axial length ≤ 19 mm (nanophthalmos);
￿ Secondary angle closure glaucoma;
￿ History of retinal ischaemia, macular oedema or wet
age-related macular degeneration;
￿ Medically unfit for surgery or for completion of the
trial.
Recruitment Procedure
Eligible patients will be identified by an ophthalmologist
(EAGLE principal local investigator or co-investigator)
during their initial consultation and noted in a log book.
When the patient returns to the clinic and if he/she is
willing to join the study, informed consent will be
obtained and physical baseline measurements taken. In
addition the patient will complete the baseline study
questionnaire (a Socio-demographic questionnaire, and
the EAGLE patient reported outcome instrument
including the NEI-VFQ25 [11], EQ-5D, GPI [5] and a
Health Care Utilisation Questionnaire). Patients will
then be randomized immediately during this appoint-
ment and informed about the allocated treatment
following full written consent collection and baseline
data completion.
Randomisation and allocation
Participants will randomized to one of the two study
groups in equal proportion using a web based randomisa-
tion application at the Study Data Centre at the Centre
for Healthcare Randomized Trials (CHaRT, http://viis.
abdn.ac.uk/HSRU/chart) in the Health Services Research
Unit, University of Aberdeen. A backup telephone
version will be available, hosted in Aberdeen. The rando-
misation algorithm will use gender, ethnicity, centre,
diagnosis (PAC or PACG), and one or both eyes eligible
as minimisation covariates [12].
Ethical approval
This study has been approved by the NRES North of Scot-
land Ethics Committee (Reference number: 08/S0802/153)
Interventions
Intervention arm: lens extraction
The patient will undergo phacoemulsification and intrao-
cular lens (IOL) implant within 60 days of randomisation
in the affected eye (Figure 1). A ‘holding treatment’ with
eye drops may be started while awaiting surgery. If both
eyes are eligible, the eye with more severe disease will be
the first to undergo surgery, followed by the second eye
within 60 days if the first intervention has been uncom-
plicated. If both eyes are equally affected participant
choice will determine the ‘index’ eye. Subsequent to lens
extraction surgery, if further treatment is required, the
same sequence of escalation of therapy as described for
‘standard care’ will be used (see below). If only one eye
meets the eligibility criteria this is the ‘index’ eye and the
fellow eye will be managed according to the clinical jud-
gement of the treating ophthalmologist and this can
involve lens extraction if this is judged to be the most
appropriate treatment plan.
The surgical intervention will be standardised by cen-
tres recruiting eligible surgeons to the following agreed
protocol regarding preoperative measures and lens
extraction:
￿ Surgeon eligibility: Fully qualified ophthalmologists
who have completed the general and specialist train-
ing (in ophthalmology and glaucoma, respectively)
will be able to perform lens extraction procedures.
￿ Lens extraction: Lens extraction will be done by
phacoemulsification. There is wide concordance
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A monofocal foldable IOL with a sharp optic edge
will be inserted [13]. Synechiolysis may be done
according to local practice and recorded. Intracam-
eral cefuroxime will be used at the end of the
procedure. Drops will be used post-operatively
according to local practice.
1. Topical anti-glaucoma medications. The topi-
cal medication will consist of eye drops accord-
ing to local protocol from the following list of
INCLUSION CRITERIA:
- Diagnosis: (1) PACG or (2) PAC with IOP > 30 mmHg at 
diagnosis
- Newly diagnosed, (i.e. either (i) untreated or (ii) under medical  
treatment for six months or less)
- Angle closure in 180 degrees or more
- Patient must be phakic in the affected eye(s)
- Participants will be  50 years
Assessed for eligibility
EXCLUDED:
- Advanced glaucoma
- Previously diagnosed acute angle closure attack in the     
otherwise eligible eye
- Increased surgical risk 
- Symptomatic cataract in either eye
- Cataract surgery or laser iridotomy in study eye 
- Axial length < 19 mm (nanophthalmos)
- Secondary angle closure glaucoma 
- Retinal ischaemia, macular oedema or wet- AMD
- Medically unfit for surgery or for completion of the trial
Standard medical treatment initiated
Informed consent
Baseline measurements taken
Randomisation to Group 1 or 2
1. Intervention Group
(Study visits at 6, 12, 24 & 36 m)
Lens extraction 
(phacoemulsification)
Escalation of medical treatment 
FAILED LENS EXTRACTION 
2. Standard Management Group
(Study visits at 6, 12, 24 & 36 m)
Laser peripheral iridotomy
Escalation of medical treatment
(+/- peripheral iridoplasty)
FAILED STANDARD CARE
Glaucoma surgery 
(e.g. trabeculectomy)
Glaucoma surgery 
(e.g., trabeculectomy)
Figure 1 Participants flow diagram.
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(OD), carbonic anhydrase inhibitor (BID), and
alpha-2 agonist (BID), pilocarpine (QID);
2. Escalation of topical anti-glaucoma medica-
tions. The sequence of escalation of therapy will
be: 1). single topical medication; 2). dual topical
therapy; 3). triple topical therapy. Laser trabecu-
loplasty may be used to supplement medical
therapy, according to local practice.
Glaucoma surgery will not be standardised. The type
of glaucoma surgery will be chosen by the surgeon
(e.g., trabeculectomy)
Control arm (standard care, Figure 1)
For those randomized to standard care intervention, both
eyes will be treated if eligible. If only one eye meets the
eligibility criteria this is the ‘Index’ eye and the fellow eye
is managed according to the clinical judgement of the
treating ophthalmologist.
Standard care will include:
1. Laser iridotomy: This will be the first treatment
step and performed according to local protocols in
each site within 60 days after randomisation. In
patients with persistent angle closure (two or more
quadrants) after laser iridotomy, laser peripheral iri-
doplasty may be done if part of local standard care;
2. Topical anti-glaucoma medications. The topical
medication will consist of eye drops according to
local protocol from the following list of medications-
prostaglandin (OD), beta-blocker (OD), carbonic
anhydrase inhibitor (BID), and alpha-2 agonist
(BID), pilocarpine (QID);
3. Escalation of topical anti-glaucoma medications.
The sequence of escalation of therapy will be: 1). single
topical medication; 2). dual topical therapy; 3). triple
topical therapy. Laser trabeculoplasty may be used to
supplement medical therapy, according to local
practice.
Those randomized to standard care will not cross-over
to lens extraction during the study period, except for a
clinical indication of cataract or only after maximum
escalation of medical treatment fails to control the IOP
and this would be considered as ‘glaucoma surgery’ (e.g.,
in those eyes with unresolved angle closure). Uncon-
trolled IOP is determined by the local ophthalmologist,
and typically additional treatment would be aiming for a
target IOP between 15-20 mmHg depending on the
degree of optic nerve damage. After medical antiglau-
coma therapy fails to control IOP, glaucoma surgery
would be initiated. The need for glaucoma surgery will
be qualified as a “failure” of the intervention/standard
care to control the disease. Patients will remain in the
trial and will continue to be followed up according to
t h ep r o t o c o l .T h et y p eo fg l a u c o m as u r g e r yw i l lb e
chosen by the surgeon (e.g., trabeculectomy).
Safety
We aim to report serious adverse events in accordance
with the guidance from the National Research Ethics
Service (NRES, http://www.nres.npsa.nhs.uk) which is a
subdivision of the National Patient Safety Agency http://
www.npsa.nhs.uk and Good Clinical Practice (GCP).
Possible (expected) intraoperative occurrences asso-
ciated with the intervention (i.e. lens extraction) are anaes-
thesia related, vitreous loss and need for anterior
vitrectomy, iris trauma, corneal wound burn, posterior
capsule rupture, lens or lens fragment loss into posterior
segment; misplaced intraocular lens, zonular dialysis,
supra-choroidal haemorrhage; and malignant glaucoma.
Possible (expected) occurrences associated with the
intervention or with standard care, occurring at any time
during the trial, include intraocular pressure spike, post-
operative inflammation, posterior capsule opacification,
malignant glaucoma, wound leakage, iris prolapse,
IOL decentration, capsular phimosis, macular oedema,
endophthalmitis, flat anterior chamber with lens-corneal
touch; retinal detachment, corneal decompensation, any
ocular surgical intervention for a complication, permanent
loss of best-corrected visual acuity greater than 10 ETDRS
letters (or two lines of Snellen chart), and systemic side
effect of ocular medication requiring hospitalisation.
Details of any of the occurrences listed above will be
recorded on the case report forms and reported to the
Data Monitoring Committee (DMC).
Outcome measures
The study has three primary outcomes - a patient-centred,
a clinical, and an economic, reflecting the multidimen-
sional nature of the possible effects the intervention may
have. These are distinct but interrelated components of
the impact of the intervention, and each component
addresses a separate dimension (and so there is no issue of
multiple comparisons). The study is adequately powered
to address each component individually.
Primary
Patient-centred: Health Status (using the EQ-5D);
Clinical: IOP at 3 year final assessment;
Economic: Incremental cost per quality adjusted life
year (QALY) gained with QALYs based on the
responses to the EQ-5D.
The EQ5D[14] is a multi-attribute health status classi-
fication system developed by EuroQol group. Each pos-
sible health state for each attributes of health status
have an assigned value or utility. EQ5D comprises five
dimensions or attribute, viz. mobility, self care, usual
activity, pain/discomfort, and anxiety/depression. This
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vention and control using the existing scoring system
the responses to the questionnaire will be used to esti-
mate health state utilities. These health state utilites
estimated each time the EQ-5D is administered will be
used to determine the QALY for each intervention
using the area under the curve method. Annual discount
rate of 3.5% will be used to discount health outcome
and cost, which is based on the recommendations of the
UK treasure and suggested by NICE [15].
Secondary
Patient-centred
Patient reported using -
￿ ag l a u c o m as p e c i f i cu t i l i t yi n s t r u m e n t( G P I )
5.T h i s
instrument is a utility-based glaucoma related health
outcome measure and has been developed using a dis-
crete choice experiment (DCE). The content of the
DCE was informed by existing profile measures rele-
vant to glaucoma to develop a preference based six-
dimensional profile instrument. The dimension
included were central and near vision; lighting and
glare; mobility, activities of daily living; eye discomfort
and other effects.
￿ a vision specific health profile measure (NEI-VFQ25)
[11]. NEI-VFQ25 is a vision specific health profile
measure based on 25-item version of National Eye
Institute Visual Function Questionnaire developed in
USA, and shorter version of 51 item NEI-VFQ [16].
The reliability and validity of NEI VFQ-25 were found
to be comparable to those of the 51 items. NEI VFQ
and suggested to be more feasible in clinical trial set-
tings where the interview lengths needs to be shorter
[11]. The multi-item subscales include items on gen-
eral health, general vision, near vision, distance vision,
driving, peripheral vision, colour vision, ocular pain
and other vision specific like role difficulties, depen-
dency, social functioning, and mental health.
Clinical
￿ need for glaucoma surgery (e.g., trabeculectomy);
best-corrected visual acuity (ETDRS) [17]; progres-
sive visual field loss [18]
￿ extension of angle closure (degrees of appositional
and synechial angle closure) determined clinically;
escalation of therapy; in those centres with imaging
equipment the opening of the anterior chamber
angle will be evaluated [19,20].
￿ number of anti-glaucoma medications; intolerance
of medications; annual incidence of acute attacks of
angle closure.
Economic
Costs will be based on resource use data [21,22]:
￿ Costs to the NHS and patients
◦ use of health services for glaucoma related
events or treatments
◦ patient costs (treatments, spectacles], travel to
health services, sick leave)
◦ need for alternative management for glaucoma
(e.g., surgery, drugs)
◦ other use of health services
▪ visits to GP
▪ visits to practice nurse
▪ visits to optometrists
Effectiveness will be based on utility estimates from
the EQ-5D and the GPI [5], and clinical outcomes
[23,24]
￿ cost-utility analysis;
￿ incremental cost per QALY based on the response
to the GPI [5].;
￿ cost-effectiveness analysis (incremental cost per
case of glaucoma surgery avoided).
Safety
Complications during or after cataract surgery; loss of
best-corrected visual acuity > 10 ETDRS letters.
The Schedule for data collection and visits is sum-
marised in Table 1.
Statistical analysis
A single main analysis will be performed at the end of
the trial when all follow-up has been completed.
Unmasked interim analyses will be conducted for the
DMC meeting as determined by their agreed terms of
reference. The statistical analysis will be based on all
participants as randomized, irrespective of subsequent
compliance with the treatment allocated.
The outcomes listed above will be compared between
the experimental and control groups using generalised
linear models (analysis of covariance) that adjust for the
minimisation factors (and where appropriate, baseline
values of outcome). Statistical significance will be at the
5% level (2P < 0.05). Analysis of co-variance will also be
used in sub-group analyses performed using interaction
terms (treatment group by subgroup) all at stricter levels
of statistical significance (2p < 0.01). All participants will
remain in their allocated group for analysis (intention to
treat). Missing data statistical modelling techniques will
be used to make use of outcome assessments prior to 3
years, and sensitivity analyses conducted to assess the
robustness of the treatment estimates to these
approaches. The type of methods that would be used
include expectation maximisation algorithm, multiple
imputation, general linear mixed models, techniques
based on survival analysis [25]. The specific missing data
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ingness has been determined.
The unit of analysis for the primary clinical outcome
will be the eye. When a participant contributes data
from two eyes the clustering will be accounted for using
random effects models. For quality of life measures the
unit of analysis will be the participant, with bilateral dis-
ease included as a covariate. Subgroup analysis of the
primary clinical outcome (IOP) will be done according
to ethnicity (Chinese or non-Chinese), and diagnosis
(PAC or PACG).
We will validate the quality of life measure (NEI-
VFQ25), in this patient group to assess sensitivity to
change of increased visual field loss [11].
Sample size
The primary patient reported quality of life outcome is
the EQ-5D. A study with 170 participants in each group
would have 90% power at 5% significance level to detect
a difference in means of 0.35 of a standard deviation
(SD). Our experience of using the EQ-5D in patients
with moderate severity of glaucoma suggests that 0.35
SD relates to a change in EQ-5D score of 0.05 [5]. Such
am e a nc h a n g ei sl i k e l yt ob eb o t hc l i n i c a l l ya n de c o -
nomically important. The primary clinical outcome of
the study will be the comparison of IOP at 3 years post
randomisation. Assuming that the standard deviation of
IOP at 3 years is about 5 mmHg in both randomized
groups (previous studies in PACG patients have
reported standard deviations from 3.6 to 4.1 [26-28] the
study would have 90% power at a 5% level of signifi-
cance to detect a mean difference in IOP between the
two groups of 1.75 mmHg. Previous studies based on
RCT evidence in open angle glaucoma have suggested
that a 2 mmHg reduction in IOP corresponds to a 20%
reduction in the risk of progression [29]. We are there-
fore confident that the study is adequately powered to
detect clinically relevant changes in IOP. The study
would also have 80% power to detect a difference of
1 5 %i nt h eg l a u c o m as u r g e r yr a t e( a s s u m i n gt h eg l a u -
coma surgery rate was 40% or less). Allowing for 15%
loss to follow-up at 3 years, the total number of partici-
pants required in the study is 400 (200 in each group).
We have conservatively powered the study on partici-
pants, not eyes.
Glossary of abbreviations
AMD: Age-related Macular Degeneration; AS-OCT: Ante-
rior Segment Optical Coherence Tomography; BID: Twice
a day; CHaRT: Centre for Healthcare Randomized Trials;
DMC: Data Monitoring Committee; EAGLE: Effectiveness
in Angle Closure Glaucoma of Lens Extraction; EQ-5D:
Table 1 Schedule for data collection and visits
Baseline +
Randomisation
Visit month 0
Visit 1
month
6
Visit 2
month
12
Visit 3
month
24
Visit 4
month
36
Medical History ✔
Consent/Randomisation ✔
Humphrey Visual Fields
1 ✔✔ ✔ ✔ ✔
Pachymetry ✔✔
Refraction ✔✔ ✔
ETDRS- Visual Acuity ✔✔ ✔
Standard clinical examination including Goldmann tonometry ✔✔ ✔ ✔ ✔
Gonioscopy ✔✔ ✔
Biometry ✔
AS- OCT/UBM
4 ✔✔
Participant completed baseline questionnaire (including socio - demographics, and outcome
instrument)
✔(IC)
Participant completed follow-up questionnaire (outcome instrument) ✔(IC) ✔(IC) ✔(IC) ✔(IC)
Health Care Utilisation Questionnaire
3 ✔(IC) ✔(IC ✔(IC) ✔(IC) ✔(IC)
Participant Cost Questionnaire
3 ✔(PA)
2
Key:
1 If unable to perform a reliable visual field, imaging of the optic nerve is required.
2 Postally administrated to participants at approximately 23 months
3 Administered in UK sites only
4 Only for centres with this technology. AS-OCT, Anterior Segment - Optical Coherence Tomography. UBM, Ultrasound Bio-Microscopy.
(IC) In clinic administration
(PA) Postal administration
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Page 7 of 10European quality of life in 5 dimensions; ETDRS: Early
Treatment Diabetic Retinopathy Study; GPI: Glaucoma
P r o f i l eI n d e x ;I O L :I n t r a o c u l a rL e n s ;I O P :I n t r a o c u l a r
Pressure; ISRCTN: International Standard Randomized
Controlled Trial Number; LI: Laser Iridotomy; LPI: Laser
Peripheral Iridoplasty; NEI-VFQ25: National Eye Institute
Visual Function Questionnaire 25; NHS: National Health
Service; NRES: National Research Ethics Service; OD:
Once a day; PAC: Primary Angle Closure; PACG: Primary
Angle Closure Glaucoma; QALY: Quality Adjusted Life
Year; QID: Four times a day; RCT: Randomized Con-
trolled Trial; SD: Standard Deviation; UBM: Ultrasound
Biomicroscopy; UK: United Kingdom; VF: Visual Field
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Appendix 1. Possible treatments for glaucoma
(eye drops)
￿ CHOLINERGIC AGENTS: PILOCARPINE (TDS or
QDS)
￿ BETA ADRENERGIC ANTAGONISTS (QD or
BDS)
￿ ALPHA AGONISTS
￿ APRACLONIDINE (TDS)
￿ BRIMONIDINE (BDS or TDS)
￿ CARBONIC ANHYDRASE INHIBITORS
￿ DORZOLAMIDE (BDS or TDS)
￿ BRINZOLAMIDE (BDS or TDS)
￿ PROSTAGLANDINS
￿ LATANOPROST (QD)
￿ TAFLUPROST (QD)
￿ BIMATOPROST (QD)
￿ TRAVAPROST (QD)
Appendix 2. Patient reported outcomes used in
EAGLE: description, scoring and interpretation
EQ-5D
EQ-5D is a generic health status instrument developed by
EuroQOL Group that can be used for clinical and eco-
nomic evaluations as well as population based surveys.
EQ-5D consists of the EQ-5D descriptive system which
provides a simple descriptive profile of health in five
dimensions: mobility, self-care, usual activities, pain, and
anxiety/depression, each with three levels. The EQ-5D
also includes a visual analogue scale on which patients
rate their own health between 0 (best imaginable health
state) and 100 (worst imaginable health state).
A single summary index can be generated by applying
a formula that attaches values to each level in each
dimension. Therefore, patient’s health state can be clas-
sified into one of the 243 theoretically possible health
states (e.g. value of full health is 11111). These value
sets are obtained using result of EQ-5D visual analogue
scale valuation or the time trade-off (TTO) valuation of
a representative sample of the population in several
countries.
Reference for EQ-5D: The Euroqol Group. Euroqol-a
faciIity for the measurement of health related quality of
life. Health policy 1990; 16:199-228. Website: http://
www.euroqol.org
NEI-VFQ 25
The NEI-VFQ 25 is a widely used vision-specific patient
reported outcome measure. It measures the impact of
vision problems on vision-targeted functioning and
health related quality of life (HR QOL). NEI-VFQ 25
consists of 25-items with 11 subscales and a single gen-
eral health rating question. A standard algorithm was
used to calculate the scale scores which vary from 0 to
100 whereby 100 is the best possible score and 0 the
worst. A composite NEI-VFQ 25 score can be generated
by averaging the eleven scores (except the general health
rating question). A higher score represents better visual
functioning.
Glaucoma Utility Index
The Glaucoma Utility Index (GUI) is a glaucoma-specific
preference based (utility) measure developed for eco-
nomic evaluation. GUI provides a descriptive profile in
six dimensions: central and near vision, lighting and
glare, mobility, activities of daily living, eye discomfort
and other effects of glaucoma and its’ treatment, each
with four levels. A single summary index can be gener-
ated where patients’ health state can be classified into
one of the 4096 theoretically possible health states. Value
sets are obtained by using results of discrete choice
experiment (DCE) of a representative sample of glau-
coma population.
Appendix 3. Charter and responsibilities of the
Data Monitoring Committee
A Data Monitoring Committee (DMC) has been estab-
lished. The DMC is independent of the study organisers.
During the period of recruitment to the study, interim
analyses will be supplied, in strict confidence, to the
DMC, together with any other analyses that the com-
mittee may request. This may include analyses of data
from other comparable trials. In the light of these
interim analyses, the DMC will advise the TSC if, in its
view:
Azuara-Blanco et al. Trials 2011, 12:133
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Page 8 of 10a) the active intervention has been proved, beyond
reasonable doubt*, to be different from the control
(standard management) for all or some types of partici-
pants, and
b) the evidence on the economic outcomes is suffi-
cient to guide a decision from health care providers
regarding recommendation of early lens extraction for
PACG.
T h eT S Cc a nt h e nd e c i d ew h e t h e ro rn o tt om o d i f y
intake to the trial. Unless this happens, however, the
TSC, PMG, clinical collaborators and study office staff
(except those who supply the confidential analyses) will
remain ignorant of the interim results.
The frequency of interim analyses will depend on the
judgement of the Chair of the DMC, in consultation
with the TSC. However, we anticipate that there might
be three interim analyses and one final analysis.
The Chair is Mr David Garway-Heath, with Dr David
Crabb, and Professor Baljean Dhillon. Terms of refer-
ence for the DMC are available on request from the
EAGLE study office.
* Appropriate criteria for proof beyond reasonable
doubt cannot be specified precisely. A difference of at
least three standard deviation in the interim analysis of
a major endpoint may be needed to justify halting, or
modifying, such a study prematurely (Peto R et al, Br J
Cancer 1976;34:548-612).
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